(UroToday.com) The American Urologic Association (AUA) annual meeting’s evolving landscape of advanced prostate cancer treatment session included a talk by Dr. Stephen Boorjian discussing bone health and radionuclide therapy. Dr. Boorjian notes that there are several clinically relevant aspects of bone health in CRPC including (i) the issue of bone loss, given that the median age of patients with CRPC is similar to the age of at-risk patients for physiologic/age-related decrease in bone mineral density (risk factors including age, previous fracture, parental history of hip fracture, low body weight, current cigarette smoking, and excessive alcohol consumption), and that ADT is associated with loss of bone mineral density (loss of 2-4% in the first year after ADT); (ii) the issue of bone metastases, given that the bone is the most frequent site of prostate cancer metastases.